HealthDay on MSN3h
SABCS: Imlunestrant Tied to Improved PFS for ER-Positive, HER2-Negative Breast Cancer With ESR1 MutationsFor patients with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast ...
Imlunestrant, an oral SERD, significantly prolonged progression-free survival in patients with advanced ER+, HER2- breast ...
Imlunestrant is being evaluated in patients with ER+/HER2- advanced breast cancer, whose disease progressed on a prior ...
An experimental drug stops advanced breast cancer from progressing in some people with tumors that have grown resistant to ...
Eli Lilly announces positive Phase III EMBER-3 trial results for imlunestrant in advanced breast cancer, showing a 38% ...
Komal Jhaveri, MD, FACP, breast oncologist and early drug development specialist at Memorial Sloan Kettering Cancer Center, ...
1d
Imlunestrant, an investigational next-generation selective estrogen receptor degrader (SERD), improved progression-free ...
Eli Lilly's Phase 3 EMBER-3 trial shows imlunestrant improves progression-free survival in advanced ER+ breast cancer ...
Imlunestrant, a next-generation SERD, improves progression-free survival in ER-positive advanced breast cancer patients ...
Imlunestrant, an investigational next-generation selective estrogen receptor degrader (SERD), improved progression-free survival in patients with endocrine therapy-pretreated, ER-positive, ...
Interim overall survival (OS) analyses at 31% maturity in patients with ESR1 mutations, and 23% maturity among all patients, ...
Eli Lilly (LLY) announced results from the Phase 3 EMBER-3 study of imlunestrant, an investigational, oral selective estrogen receptor ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback